Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sepsis Drug Risks

Sepsis Drug Risks Reports of serious bleeding and deaths among patients treated for severe sepsis with a recombinant form of human activated protein C, drotrecogin alfa, have prompted the US Food and Drug Administration (FDA) to evaluate these safety concerns, according to an early communication from the agency. According to the FDA, after a recent retrospective study suggested that patients with severe sepsis and certain concurrent risk factors for bleeding may be more likely than patients without such risk factors to experience serious bleeding when taking drotrecogin alfa activated, the agency and the drug maker decided to reevaluate the potential problems associated with this drug. A review of the medical records of 73 patients who were treated with drotrecogin alfa activated found that serious bleeding occurred in 7 of the 20 patients (35%) who had a concurrent elevated risk of bleeding compared with 2 of 53 patients (3.8%) without these factors (Gentry CA et al. Crit Care Med. 2009;37[1]:19-25). Patients with bleeding risk factors also were more likely to die; 13 of the 20 such patients (65%) died of any cause compared with 13 of 53 (24.5%) of those without such factors. Currently, the label for this product warns that a careful risk-benefit analysis is necessary before administering it to patients at risk for bleeding. The authors suggest avoiding the use of drotrecogin alfa activated in such high-risk patients, and call for further studies in larger populations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Sepsis Drug Risks

JAMA , Volume 301 (12) – Mar 25, 2009

Sepsis Drug Risks

Abstract

Reports of serious bleeding and deaths among patients treated for severe sepsis with a recombinant form of human activated protein C, drotrecogin alfa, have prompted the US Food and Drug Administration (FDA) to evaluate these safety concerns, according to an early communication from the agency. According to the FDA, after a recent retrospective study suggested that patients with severe sepsis and certain concurrent risk factors for bleeding may be more likely than patients without such risk...
Loading next page...
 
/lp/american-medical-association/sepsis-drug-risks-36mtTiGUuh

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 2009 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.374
Publisher site
See Article on Publisher Site

Abstract

Reports of serious bleeding and deaths among patients treated for severe sepsis with a recombinant form of human activated protein C, drotrecogin alfa, have prompted the US Food and Drug Administration (FDA) to evaluate these safety concerns, according to an early communication from the agency. According to the FDA, after a recent retrospective study suggested that patients with severe sepsis and certain concurrent risk factors for bleeding may be more likely than patients without such risk factors to experience serious bleeding when taking drotrecogin alfa activated, the agency and the drug maker decided to reevaluate the potential problems associated with this drug. A review of the medical records of 73 patients who were treated with drotrecogin alfa activated found that serious bleeding occurred in 7 of the 20 patients (35%) who had a concurrent elevated risk of bleeding compared with 2 of 53 patients (3.8%) without these factors (Gentry CA et al. Crit Care Med. 2009;37[1]:19-25). Patients with bleeding risk factors also were more likely to die; 13 of the 20 such patients (65%) died of any cause compared with 13 of 53 (24.5%) of those without such factors. Currently, the label for this product warns that a careful risk-benefit analysis is necessary before administering it to patients at risk for bleeding. The authors suggest avoiding the use of drotrecogin alfa activated in such high-risk patients, and call for further studies in larger populations.

Journal

JAMAAmerican Medical Association

Published: Mar 25, 2009

Keywords: sepsis

There are no references for this article.